Skip to main content

Table 1 Characteristics of our series of 2493 patients

From: Beyond D’Amico risk classes for predicting recurrence after external beam radiotherapy for prostate cancer: the Candiolo classifier

Features
Follow-up, months  
 Mean (SD) 56 (36)
 Median (Min-Max) 50 (4–159)
 FU ≥ 2-yy, no (%) 2018 (81 %)
 FU ≥ 5-yy, no (%) 982 (39 %)
 FU ≥ 7-yy, no (%) 481 (19 %)
 FU ≥ 10-yy, no (%) 179 (7 %)
Age, yr  
 Mean (SD) 71.7 (5.9)
 Median (Min-Max) 73 (43–86)
PSA, ng/ml  
 Mean (SD) 15.0 (26.0)
 Median (Min-Max) 8.6 (0.39-749)
Tumor Stage, %  
 cT1 30.5 %
 cT2 57.5 %
 cT3-4 12 %
Bone Scan staging  
 Performed 67 %
 Not performed 33 %
Abdominal CT staging  
 Performed 59 %
 Not performed 41 %
Endo-coil or pelvic MRI staging  
 Performed 15 %
 Not performed 85 %
TRUS  
 Performed 49 %
 Not performed 51 %
Biopsic Gleason Score, %  
 ≤6 48 %
 3 + 4 22 %
 4 + 3 11.5 %
 8 12 %
 9-10 6.5 %
D’Amico Risk Classification, %  
 Low 21.5 %
 Intermediate 32 %
 High 46.5 %
Biopsy cores sampled, no  
 Mean (SD) 10.3 (4.2)
 Median (Min-Max) 10 (2–42)
% Positive Cores, %  
 Mean (SD) 44.3 % (28.0 %)
 Median (Min-Max) 40 % (3-100 %)
RT Dose, ED2Gy  
 Mean (SD) 75.5 (3.0)
 Median (Min-Max) 76.0 (67.1-81.1)
RT alone, % 38 %
RT plus ADT, % 62 %
  1. SD Standard deviation, TRUS Trans rectal ultra-sound, ED2Gy Equivalent dose at standard 2 Gy dose per fraction, RT Radiation therapy, ADT Androgen deprivation therapy